Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Orionis Biosciences has debuted with a 4-year pact with the big drug company Novartis to develop allosterically acting small molecules that when bound to a protein change its conformation to allow binding to a protein target of interest. That protein-protein interaction could prompt the target to be turned off, modulated, or broken down. Orionis says its allosteric-binding technology, which it calls Allo-Glue, could allow it to access previously intractable protein targets. As part of the deal, Novartis is providing undisclosed research funding and investment in the firm.
This article has been sent to the following recipient: